



NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK

March 25, 2024

RADNOR, Pa., March 25, 2024 [/PRNewswire/](#) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024, at the Blavatnik School of Government in Oxford, UK.

The Ketamine 2024 Conference assembles many of the top scientists and clinicians in the field from around the world and is a forum for top researchers and experienced and interested clinicians to learn from each other about the therapeutic use of Ketamine and related compounds for affective disorders. Dr. Javitt will present a keynote talk titled, "Ketamine: the Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced." He will present an overview of the rapid and dramatic efficacy of Ketamine in the treatment of acute suicidality as well as recent science documenting the potential for neurotoxicity with long-term CNS side effects if ketamine is used without appropriate safety controls as a long-term drug.

"HOPE Therapeutics builds upon four decades of scientific discovery related to the role of the brain's NMDA receptor and the effects of ketamine and other NMDA-antagonist drugs in rapidly attenuating symptoms of depression and suicidality. It is an honor for our company to be invited to share a platform with those who have established this field of science and who may forever change the outlook and future path of patients who suffer from suicidal depression and PTSD," said Dr. Javitt.

Ketamine 2024 Conference Presentation

When: Monday, March 25th, 2024

Time: 1:40-2:00 PM GMT

Title: Ketamine: The Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRx Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially

different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at <http://www.sec.gov>. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE NRx Pharmaceuticals, Inc.